Evidence map›Paper›PMID 36982778›Full record

ArticleInternational journal of molecular sciences2023

Myeloperoxidase PET Imaging Tracks Intracellular and Extracellular Treatment Changes in Experimental Myocardial Infarction.

Matthias W G Zeller, Cuihua Wang, Edmund J Keliher, Gregory R Wojtkiewicz, Aaron Aguirre, Kevin Maresca, Chunyan Su, Leonard Buckbinder, Jing Wang, Matthias Nahrendorf and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Molecular contrast agents for post-infarct cardiac remodelling: a contemporary review.European heart journal. Imaging methods and practice · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Matthias W G ZellerInstitute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA 02129, USA.ORCID 0000-0002-6288-5639
Cuihua WangInstitute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA 02129, USA.
Edmund J KeliherCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Gregory R WojtkiewiczCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Aaron AguirreCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Kevin MarescaPfizer World Wide Research and Development, Cambridge, MA 02139, USA.
Chunyan SuPfizer World Wide Research and Development, Cambridge, MA 02139, USA.
Leonard BuckbinderPfizer World Wide Research and Development, Cambridge, MA 02139, USA.
Jing WangInstitute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA 02129, USA.
Matthias NahrendorfCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
John W ChenInstitute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA 02129, USA.
Harvard University · USPfizer (United States) · US

Funding

Imaging macrophage and microglial functional diversity in strokeR01NS103998 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CHEN, JOHN W · 2018 to 2022
$2.6M
Tracking M2-Like Macrophages in Cardiopulmonary Diseases by Magnetic Resonance ImagingK25HL150305 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI WANG, CUIHUA · 2020 to 2024
$763k
National Institute of Health K25HL150305National Multiple Sclerosis Society RG-1902-33633NHLBI NIH HHS K25 HL150305NIH HHS R01NS103998NINDS NIH HHS R01 NS103998Pfizer N/A
6 · The paper itself

Abstract

Myeloperoxidase (MPO) is a highly oxidative, pro-inflammatory enzyme involved in post-myocardial infarction (MI) injury and is a potential therapeutic target. While multiple MPO inhibitors have been developed, the lack of an imaging reporter to select appropriate patients and assess therapeutic efficacy has hampered clinical development. Thus, a translational imaging method to detect MPO activity non-invasively would help to better understand the role MPO plays in MI and facilitate novel therapy development and clinical validation. Interestingly, many MPO inhibitors affect both intracellular and extracellular MPO, but previous MPO imaging methods can only report extracellular MPO activity. In this study, we found that an MPO-specific PET imaging agent (

Indexed as

Myocardial InfarctionPeroxidaseHumansPositron-Emission TomographyPeroxidase18F-MAPPdamaging inflammationintracellular and extracellular MPOMPO inhibitormyeloperoxidasemyocardial infarctionPET imaging

Identifiers

PMID36982778
PMCPMC10057533
OpenAlexW4327730979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.